Search research articles
Contact Us
Filters
Showing results (31-40 of 42) with videos related to
Page
of 5
Sort By:
Arthritis Research & Therapy
|
May 12, 2019
Long-term experience with apremilast in patients with psoriatic arthritis: 5-year results from a PALACE 1-3 pooled analysis
Arthur Kavanaugh, Dafna D Gladman, Christopher J Edwards, et al.
Rheumatology (Oxford, England)
|
June 8, 2021
Apremilast monotherapy for long-term treatment of active psoriatic arthritis in DMARD-naïve patients
Alvin F Wells, Christopher J Edwards, Alan J Kivitz, et al.
Rheumatology and Therapy
|
September 18, 2021
Articular and Extra-Articular Benefits in ACR20 Non-responders at Week 104 Treated With Apremilast: Pooled Analysis of Three Randomized Controlled Trials
Philip J Mease, Dafna D Gladman, Arthur Kavanaugh, et al.
The Journal of Rheumatology
|
April 16, 2022
Baseline Disease Activity Predicts Achievement of cDAPSA Treatment Targets With Apremilast: Phase III Results in DMARD-naïve Patients With Psoriatic Arthritis
Philip J Mease, Arthur Kavanaugh, Alexis Ogdie, et al.
Oncology Letters
|
July 17, 2018
Caspase-10, matrix metalloproteinase-9 and total laminin are correlated with the tumor malignancy of clear cell renal cell carcinoma
Hua Qian, Xiaoguang Li, Wei Zhang, et al.
ACR Open Rheumatology
|
July 26, 2020
Long-Term Safety and Tolerability of Apremilast Versus Placebo in Psoriatic Arthritis: A Pooled Safety Analysis of Three Phase III, Randomized, Controlled Trials
Philip J Mease, Dafna D Gladman, Juan J Gomez-Reino, et al.
Arthritis Care & Research
|
January 8, 2020
Treatment-to-Target With Apremilast in Psoriatic Arthritis: The Probability of Achieving Targets and Comprehensive Control of Disease Manifestations
Philip J Mease, Dafna D Gladman, Alexis Ogdie, et al.
Journal of Endourology
|
July 25, 2025
Perioperative Outcomes of Robot-Assisted Partial Nephrectomy with MP1000 Surgical System <i>vs</i> da Vinci Xi Surgical System and Evaluation of the MP1000 Learning Curve
Honglei Wang, Ziyu Dong, Radheshyam Gupta, et al.
RMD Open
|
July 19, 2018
Therapeutic benefit of apremilast on enthesitis and dactylitis in patients with psoriatic arthritis: a pooled analysis of the PALACE 1-3 studies
Dafna D Gladman, Arthur Kavanaugh, Juan J Gómez-Reino, et al.
Rheumatology (Oxford, England)
|
July 1, 2026
Progression from oligoarticular to polyarticular psoriatic arthritis and apremilast as a disease modifier: novel insights from FOREMOST
Laura C Coates, Dafna D Gladman, Joseph F Merola, et al.
Page
of 5
Search research articles
Search
Showing results (31-40 of 42) with videos related to
Sort By:
Page
of 5
Arthritis Research & Therapy
|
May 12, 2019
Long-term experience with apremilast in patients with psoriatic arthritis: 5-year results from a PALACE 1-3 pooled analysis
Arthur Kavanaugh, Dafna D Gladman, Christopher J Edwards, et al.
Rheumatology (Oxford, England)
|
June 8, 2021
Apremilast monotherapy for long-term treatment of active psoriatic arthritis in DMARD-naïve patients
Alvin F Wells, Christopher J Edwards, Alan J Kivitz, et al.
Rheumatology and Therapy
|
September 18, 2021
Articular and Extra-Articular Benefits in ACR20 Non-responders at Week 104 Treated With Apremilast: Pooled Analysis of Three Randomized Controlled Trials
Philip J Mease, Dafna D Gladman, Arthur Kavanaugh, et al.
The Journal of Rheumatology
|
April 16, 2022
Baseline Disease Activity Predicts Achievement of cDAPSA Treatment Targets With Apremilast: Phase III Results in DMARD-naïve Patients With Psoriatic Arthritis
Philip J Mease, Arthur Kavanaugh, Alexis Ogdie, et al.
Oncology Letters
|
July 17, 2018
Caspase-10, matrix metalloproteinase-9 and total laminin are correlated with the tumor malignancy of clear cell renal cell carcinoma
Hua Qian, Xiaoguang Li, Wei Zhang, et al.
ACR Open Rheumatology
|
July 26, 2020
Long-Term Safety and Tolerability of Apremilast Versus Placebo in Psoriatic Arthritis: A Pooled Safety Analysis of Three Phase III, Randomized, Controlled Trials
Philip J Mease, Dafna D Gladman, Juan J Gomez-Reino, et al.
Arthritis Care & Research
|
January 8, 2020
Treatment-to-Target With Apremilast in Psoriatic Arthritis: The Probability of Achieving Targets and Comprehensive Control of Disease Manifestations
Philip J Mease, Dafna D Gladman, Alexis Ogdie, et al.
Journal of Endourology
|
July 25, 2025
Perioperative Outcomes of Robot-Assisted Partial Nephrectomy with MP1000 Surgical System <i>vs</i> da Vinci Xi Surgical System and Evaluation of the MP1000 Learning Curve
Honglei Wang, Ziyu Dong, Radheshyam Gupta, et al.
RMD Open
|
July 19, 2018
Therapeutic benefit of apremilast on enthesitis and dactylitis in patients with psoriatic arthritis: a pooled analysis of the PALACE 1-3 studies
Dafna D Gladman, Arthur Kavanaugh, Juan J Gómez-Reino, et al.
Rheumatology (Oxford, England)
|
July 1, 2026
Progression from oligoarticular to polyarticular psoriatic arthritis and apremilast as a disease modifier: novel insights from FOREMOST
Laura C Coates, Dafna D Gladman, Joseph F Merola, et al.
Page
of 5